Clik here to view.
Catalyst Pharmaceuticals Announces Date and Time Change for Fourth Quarter...
CORAL GABLES, Fla., March 12, 2018 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for...
View ArticleClik here to view.
Catalyst Pharmaceuticals Announces Submission of New Drug Application for...
CORAL GABLES, Fla., March 29, 2018 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for...
View ArticleClik here to view.
Catalyst Pharmaceuticals Announces FDA Acceptance of NDA and Priority Review...
–PDUFA Date Set for November 28, 2018 CORAL GABLES, Fla., May 29, 2018 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and...
View ArticleClik here to view.
Catalyst Pharmaceuticals Appoints Daniel J. Brennan as Chief Commercial Officer
CORAL GABLES, Fla., June 13, 2018 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies...
View ArticleClik here to view.
Patients and Biopharma: Trusted Partners in Fighting Rare Diseases
Significant advances have been made in fighting rare diseases over the past decades. In the 10 years prior to the passage of the Orphan Drug Act in 1983, fewer than 10 drugs for rare diseases were...
View ArticleClik here to view.
Catalyst Pharmaceuticals Expands Commercial Leadership Team
Augments Medical Affairs Team with 3 Additional Medical Science Liaisons CORAL GABLES, Fla., Aug. 06, 2018 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a...
View ArticleClik here to view.
Catalyst Neuromuscular Connections
Click here to download this issue as a PDF. You are being redirected to a product website. Do you wish to continue? Yes No The post Catalyst Neuromuscular Connections appeared first on...
View ArticleClik here to view.
FDA Approves Firdapse® (amifampridine) for the Treatment of Lambert-Eaton...
FDA Approves Firdapse® (amifampridine) for the Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) – First evidenced-based medicine approved to treat LEMS – Catalyst Pathways™ designed to facilitate...
View ArticleClik here to view.
Catalyst Pharmaceuticals Holds Investor Call to Discuss FIRDAPSE®...
CORAL GABLES, Fla., December 13, 2018 – Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people...
View ArticleClik here to view.
Hello world!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing! You are being redirected to a product website. Do you wish to continue? Yes No The post Hello world! appeared...
View Article